Work

Early introduction of trastuzumab deruxtecan (T-DXd) in HER2 expressing rare gynecologic malignancies – How early is too early?

Year: 2025

Type: editorial

Source: Gynecologic Oncology Reports

DOI: 10.1016/j.gore.2025.101965

Authors: Jennifer McEachron, Jamie N. Bakkum-Gamez

Institutions: Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota)

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $930

Funder: Mayo Foundation for Medical Education and Research

OpenAlex ID: W4414716185

Cites: 11

Cited by:

Related to: